MicrobioSeq Presents a Fungal Whole Genome De Novo Sequencing Platform to Facilitate Microbial Research

To help scientific researchers better understand the biodiversity, physiology, metabolism, and function of fungi, CD Genomics MicrobioSeq has launched the Fungal Whole Genome De Novo Sequencing Service.

New York, United States – April 25, 2022 – MicrobioSeq is the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics services company with a reputation for providing reliable sequencing, genotyping, microarray and bioinformatics services. To help scientific researchers better understand the biodiversity, physiology, metabolism, and function of fungi, CD Genomics MicrobioSeq has launched the Fungal Whole Genome De Novo Sequencing Service.

Fungi are vital to the biosphere and human health due to their significant medical and economic value. Some fungi are closely related to animals, plants, and other life forms by developing symbiotic relationships. Fungi also produce some secondary metabolites, such as penicillin, cyclosporine, and lovastatin, which have important medicinal, agricultural, or cosmetic benefits.

Fungal genome research is a method to obtain the complete fungal genome sequence by genome sequencing and assembly, and to study its structure and function. Extensive research on these strains also allows us to better understand and utilize fungal resources to create greater value.

Traditional techniques cannot handle the large amount of data required for fungal genome-wide research because fungal genomes are typically large and complex. At present, the combined assembly strategy of short-read and long-read sequencing can realize the advanced mushroom assembly, and some projects can be assembled at the level close to the completed board, which provides strong support looking for mushrooms.

“CD Genomics uses both long-read and short-read sequencing technologies for fungal whole genome de novo sequencing. The PacBio and Nanopore platforms are superior long-read sequencing platforms that generate reads with tens of kilobases in length for better genome reconstruction. A single DNA molecule can be sequenced without requiring PCR amplification or chemical labeling of the sample. De novo assembly from long reads can cover low complexity and repetitive regions and create precise assemblies. Additionally, we are performing fungal whole genome de novo sequencing on Illumina HiSeq, which is a short-read sequencing platform with high accuracy,” said Dianna, CMO of CD Genomics.

“Fungal whole genome de novo sequencing, which is used to study new fungal populations, allows reconstruction of fungal genomes, functional analyzes and evolutionary studies. This technique can shed light on the biological diversity of fungi and yeasts, extending research to agricultural sciences, ecology, bioremediation, medical sciences, cosmetic sciences, bioenergy and biotechnology,” she added.

Benefits of CD Genomics Fungal Whole Genome De Novo Sequencing:

1. Lesser degree of bias and longer read lengths (mean >15,000 bp, some reads >100,000 bp) generated by long read sequencing instruments.

2. Advanced sequencing platforms: Illumina HiSeq, Nanopore MinION and PacBio Sequel platforms.

3. Extensive experience in the genomics service industry.

4. Professional bioinformatics analysis team.

About the MicrobioSeq Division of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, which is a genomics services company with a reputation for providing reliable microbial sampling products, microbial testing services, microbial genomics services and integrated bioinformatics.

Media Contact
Company Name: CD Genomics
Contact person: Kiko Garcia
E-mail: Send an email
Call: 1-631-259-7705
Country: United States
Website: https://www.cd-genomics.com

About Lucille Thompson

Check Also

The resort drives change with Qld-first green initiative

A boutique backpacker resort is setting the standard for sustainable practices, with a first initiative …